Zhang YF, Xu R, Luo J, Ma Y, Xiao G, Liu Y. Identification of Mannose-Capped-Arabinomannan 101-mer as a Potential Influenza Virus Vaccine Adjuvant. Adv Sci (Weinh). 2026 Feb 3:e19843
Many natural bacterial components as adjuvants can activate the host immune system, but the excessive toxicity and structure-identification challenge limit their applications and structure-activity relationship studies. Herein, we report the role of a series of chemically synthesized mannose-capped arabinomannan motifs from Mycobacterium tuberculosis cell wall, including 18-mer, 19-mer, 27-mer, and 101-mer in regulating host immunity. As an influenza vaccine adjuvant, 101-mer induced significantly enhanced anti-influenza antibody response and immune protection compared with other arabinomannan motifs. 101-mer elicited robust immunoenhancement while exhibiting a favorable tolerability profile, as it did not trigger any observable physiological toxicity or inflammatory reactions in various organs. Mechanistically, we found 101-mer may serve as a Dectin-2 agonist to activate host immunity through Syk/NF-κB signaling. This study provided a new oligosaccharide candidate that can satisfy the required "efficacy-safety" balance for clinical adjuvant development.
See Also:
Latest articles in those days:
- [preprint]Emergence and antigenic characterisation of influenza A(H3N2) viruses with hemagglutinin substitutions N158K and K189R during the 2024/25 influenza season 13 hours ago
- Epitope specificity shapes the CD4+ T cell response to influenza virus infection in mice 13 hours ago
- Vaccination against H5 HP avian influenza virus leads to persistent immune response in wild king penguins 1 days ago
- Molecular Epidemiology and Genetic Diversity of Influenza B Viruses Based on Whole-Genome Analysis in Japan and Myanmar, 2016-2020 1 days ago
- Assessing HPAI-H5 transmission risk across wild bird migratory flyways in the United States 1 days ago
[Go Top] [Close Window]


